Cargando…

A randomized crossover study of single biweekly administration of epoetin-α compared with darbepoetin-α in chronic kidney disease patients not receiving dialysis

BACKGROUND: Recent evidence demonstrates that high doses of epoetin-alpha (EPO-α) can be administrated at extended intervals, despite its relatively short serum half-life. However, no prospective randomized trials on the effects of extended dosing intervals of EPO-α compared with darbepoetin-alpha (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Na, Ha-Young, Lee, Yong-Kyu, Shin, Sug-Kyun, Yang, Dong-Ho, Cheon, Woong, Park, Jung-Hwan, Lee, Jong-Ho, Song, Jong-Oh, Jo, Young-Il
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714283/ https://www.ncbi.nlm.nih.gov/pubmed/26885479 http://dx.doi.org/10.1016/j.krcp.2014.10.001

Ejemplares similares

Darbepoetin Versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment
por: Ots, Pilar Ma Samper, et al.
Publicado: (2008)

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
por: Arrieta, Javier, et al.
Publicado: (2014)

A Comparative Study of the Hemoglobin-Maintaining Effects Between Epoetin-β Pegol and Darbepoetin-α in Patients with Chronic Kidney Disease During 3 Months Before Dialysis Initiation
por: Oka, Satoru, et al.
Publicado: (2017)

A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A “Half-and-Half” Combination Therapy()
por: Shimamatsu, Kazumasa, et al.
Publicado: (2013)

Clinical usefulness of bioimpedance analysis for assessing volume status in patients receiving maintenance dialysis
por: Park, Jung Hwan, et al.
Publicado: (2018)

Effect of occasional epoetin use in combination with a stable darbepoetin dosage on anemia management in hemodialysis patients
por: Shimamatsu, Kazumasa
Publicado: (2014)

Costs Associated With Intravenous Darbepoetin Versus Epoetin Therapy in Hemodialysis Patients: A Randomized Controlled Trial
por: Woodland, Andrea L., et al.
Publicado: (2017)

Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents
por: Lee, Sung-Eun, et al.
Publicado: (2018)

Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study
por: Choi, Peter, et al.
Publicado: (2013)

The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients
por: AlKharboush, Hanan, et al.
Publicado: (2020)

The Use of Epoetin-α in Revision Knee Arthroplasty
por: Delasotta, Lawrence A., et al.
Publicado: (2012)

Antibody-mediated pure red cell aplasia (PRCA) on switching from darbepoetin alfa to epoetin beta: what are the implications?
por: Assunção, José, et al.
Publicado: (2008)

The Use of Preoperative Epoetin-α in Revision Hip Arthroplasty
por: Delasotta, Lawrence A, et al.
Publicado: (2012)

Extended dosing of darbepoetin alfa in peritoneal dialysis patients
por: Feriani, Mariano, et al.
Publicado: (2011)

A proposal of the simple guide regarding the conversion ratio from epoetin to darbepoetin alpha in treating haemodialysis patients with renal anaemia
por: Nakagawa, Tetsuya
Publicado: (2008)

Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme
por: Greulich, Timm, et al.
Publicado: (2018)

Biweekly Irinotecan and Cisplatin as Second-line Chemotherapy in Pretreated Patients with Advanced Gastric Cancer: A Multicenter Phase II Study
por: Baek, Jin Ho, et al.
Publicado: (2005)

Antioxidant and antiapoptotic effects of darbepoetin-α against traumatic brain injury in rats
por: Kertmen, Hayri, et al.
Publicado: (2015)

Darbepoetin-α increases the blood volume flow in transplanted pancreatic islets in mice
por: Menger, Maximilian M., et al.
Publicado: (2020)

Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study
por: Donck, Jan, et al.
Publicado: (2014)

Correction to: Darbepoetin-α increases the blood volume flow in transplanted pancreatic islets in mice
por: Menger, Maximilian M., et al.
Publicado: (2021)

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial
por: Carrera, Fernando, et al.
Publicado: (2010)

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
por: McGarvey, November, et al.
Publicado: (2015)

New oral spherical carbon adsorbent effectively reduces serum indoxyl sulfate levels in moderate to advanced chronic kidney disease patients: a multicenter, prospective, open-label study
por: Kim, Seok-hyung, et al.
Publicado: (2020)

Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer
por: Chon, Hong Jae, et al.
Publicado: (2011)

Stenotrophomonas Maltophilia Infection in Patients Receiving Continuous Ambulatory Peritoneal Dialysis
por: Baek, Joo-Eun, et al.
Publicado: (2004)

Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study
por: Galle, Jan-Christoph, et al.
Publicado: (2016)

The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Blockers
por: Byun, Ja Min, et al.
Publicado: (2015)

Improvement in Erythropoieis-stimulating Agent-induced Pure Red-cell Aplasia by Introduction of Darbepoetin-α When the Anti-erythropoietin Antibody Titer Declines Spontaneously
por: Lee, Hajeong, et al.
Publicado: (2010)

Transfusion-dependent anaemia treatment using continuous erythropoietin receptor activator (epoetin β pegol) and roxadustat after darbepoetin treatment failure in low-risk myelodysplastic syndrome: a case report
por: Ikenoue, Tatsuyoshi, et al.
Publicado: (2021)

Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage
por: Furukawa, Tetsuya, et al.
Publicado: (2015)

Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial
por: Jo, Young-Il, et al.
Publicado: (2016)

Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen)
por: East, Cara, et al.
Publicado: (2022)

Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open‐label, parallel‐group, noninferiority phase III trial
por: Liu, Bicheng, et al.
Publicado: (2022)

Should We Use Preoperative Epoetin-α in the Mildly Anemic Patient Undergoing Simultaneous Total Knee Arthroplasty?
por: Delasotta, Lawrence A, et al.
Publicado: (2013)

Pretreatment with Darbepoetin Attenuates Renal Injury in a Rat Model of Cisplatin-Induced Nephrotoxicity
por: Choi, Dae Eun, et al.
Publicado: (2009)

A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer
por: Kim, Hae Su, et al.
Publicado: (2017)

Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan
por: Hayashi, Terumasa, et al.
Publicado: (2020)

Higher Peritoneal Protein Clearance as a Risk Factor for Cardiovascular Disease in Peritoneal Dialysis Patient
por: Chang, Tae Ik, et al.
Publicado: (2013)

TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patients
por: Gaweda, Adam E, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_egiebq93l90a5bi2ukm2nq7g3p